Bastion Therapeutics’ Post

Could a game-changing solution to the treatment of solid tumors and autoimmune diseases be on the horizon? A fascinating new article from UKT news dives into the remarkable possibilities of T-Cypher Bio's D-Cypher, an integrated platform that could potentially revolutionize the biotech industry. This Oxford-based startup are planning to overcome the challenges met with current therapeutics, as they push the boundaries of science to transform lives. Don't miss out on this enlightening read: https://UKT.news/?p=10417 #Biotech #HealthcareInnovation #TCRBiotherapeutics #DCypher #OxfordStartup

𝐅𝐥𝐚𝐠𝐬𝐡𝐢𝐩 𝐏𝐢𝐨𝐧𝐞𝐞𝐫𝐢𝐧𝐠 𝐋𝐚𝐮𝐧𝐜𝐡𝐞𝐬 𝐏𝐫𝐨𝐥𝐨𝐠𝐮𝐞 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬: 𝐋𝐞𝐯𝐞𝐫𝐚𝐠𝐢𝐧𝐠 𝐕𝐢𝐫𝐚𝐥 𝐏𝐫𝐨𝐭𝐞𝐢𝐧𝐬 𝐟𝐨𝐫 𝐃𝐫𝐮𝐠 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 Flagship Pioneering Flagship Pioneering's latest venture, Prologue Medicines Prologue Medicines, has launched with a $50 million investment to propel its innovative DELVE platform. DELVE, a cutting-edge proteome-assisted drug discovery technology, capitalizes on the expansive viral proteome to identify potential therapeutic molecules. Under the leadership of CEO Lovisa Afzelius Lovisa Afzelius, Prologue is dedicated to developing a robust pipeline of drug candidates, with a primary focus on cancer, metabolic, and immunology indications. Afzelius, alongside co-founders Theonie Anastassiadis and Hozefa Bandukwala, envisions Prologue as a frontrunner in leveraging viral proteins for medical advancements. With Noubar Afeyan as chairman, Prologue stands as a significant addition to Flagship's portfolio, which also includes Empress Therapeutics and ProFound Therapeutics. This strategic move reinforces Flagship's commitment to pioneering breakthroughs in the life sciences sector. #PrologueMedicines #DrugDiscovery #ViralProteins #FlagshipPioneering #DELVEPlatform #TherapeuticMolecules #HealthcareInnovation #InvestmentInScience

📣 Calling Supply Chain, Logistics and Clinical Operations Leaders!   🌐 We are excited to announce the only meeting uniting experts from logistics and clinical operations teams to collaboratively solve the challenges facing the supply chains critical to Cell Therapy.   ⬇ Check out the post below to get caught up on all the information regarding the 5th Supply Chain and Logistics for Cell Therapies Summit, as the community aims to streamline supply chains to get therapies to patients faster! #supplychain #celltherapy #clinicaloperations #cellandgene #logistics

CA-based CuraSen Therapeutics Raises $5.8M in #Funding from the Alzheimer’s Drug Discovery Foundation (ADDF) to advance CST-3056, an alpha-1A adrenoceptor (α1A-AR) agonist for the #treatment of Alzheimer’s #disease. for the #Treatment of Alzheimer’s Disease. Anthony Ford, PhD, chief executive officer, CuraSen Therapeutics said, “We are thrilled to receive this #investment from the Alzheimer’s Drug Discovery #Foundation which will be used to advance CST-3056, our proprietary α1A-AR agonist program, from preclinical #development to #completion of Phase 1 studies, “Coupled with our two other Phase 2 clinical-stage programs in #neurodegenerative diseases, CST-2032 and CST-103, CuraSen is well-positioned to #deliver #critically needed neurodegenerative disease treatment options to the millions of #patients and caregivers in need.” CuraSen is #focused on the #development of new #treatments for neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease and other related #orphan conditions. CuraSen Therapeutics, Inc. Alzheimer's Drug Discovery Foundation Anthony Ford #curasentherapeutics #funding #startup

Lamassu BioTech is ready for Biotechnology Innovation Organization’s #BIO2024 Conference! 🔬 Lamassu CEO Gabi Hanna MD., will be in San Diego throughout #BIO2024, meeting with other leaders in the #biotech industry and exploring opportunities to accelerate hope and healing. Lamassu is transforming the way we treat metastatic cancer and solving the critical unmet medical need of severe acute pancreatitis. SA53, a #noveltherapeutic that targets p53 wild-type sarcomas, has demonstrated remarkable potency, efficacy and safety in preclinical models, positioning it for an Investigational New Drug (IND) submission that was recently approved by the FDA. This potential best-in-class #precisionmedicines offers new hope for #metastitic #cancertreatment. Companies and investors interested in targeted cancer therapies, or anyone interested in learning about our team’s works, should use the contact form on our website, https://lnkd.in/gnvwYBm, to schedule a meeting during #BIO2024.

Phialogics is a preclinical biotech company specialized in engineering next-generation biologics to rebalance the immune response in acute and chronic inflammation. Phialogics concept is based on the targeted modification of immunoglobulin receptor domains (IgVs) to modulate immune response in inflammatory diseases. IgV mediated receptor-ligand interaction represents a significant source of novel biologics. Phialogics lead molecules replicate endogenous protein-protein interactions to efficiently modulate the function of their target receptor. So far, only this unique platform technology can achieve such a high level of precision. Meet Phialogics AG @ #Sachs_ELSF More Info @ https://lnkd.in/dQWhKYkV #ELSF2024 #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #RisingStars #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #SachsSpringLifeSciencesWeek #SSLSW

The search for effective treatments for inflammatory bowel disease is driven by advancements in preclinical research employing diverse IBD mouse models. Choosing a mouse model for IBD preclinical studies is not always straightforward but is a prerequisite for reliable outcomes. Join this Tech Talk to gain expert guidance on the advantages and disadvantages of different irritable bowel disease models.

🌟 Weekly Biotech Buzz 🧬💡 As we gear up for the holiday season, it's exciting to see the biotech industry thriving with innovation and success! 🎄✨ This week in biotech has been a whirlwind of activity: Pharvaris made a splash with a $300M public offering, highlighting its progress in hereditary angioedema treatment. 💊🔬 SpringWorks Therapeutics closed a notable $316.25M public offering, paving the way for new treatments in desmoid tumors. 🎯🧪 EyePoint Pharmaceuticals secured a substantial $230M, focusing on advancing AMD treatments. 👁️🗨️💫 New kid on the block, Tome Biosciences, launched with a massive $213M funding, aiming to revolutionize genomic medicines. 🧬🚀 Bicara Therapeutics received a $165M boost to develop innovative cancer treatments. 🎗️💪 The industry's dynamism and resilience are more evident than ever as we approach 2024. Let's keep pushing the boundaries of medical science and improving lives! #Biotech #Innovation #Funding #MedicalAdvancements #HolidaySeason

🌟 Join Us for the Donor Selection and Cell Source Summit! 🌟 The cell therapy field is at the forefront of a revolution, especially in developing treatments for autoimmune patients. With over 150+ clinical trials currently underway and recent FDA approvals for allogeneic cell products, the momentum in this space is undeniable. 🚀 As the allogeneic cell therapy field continues to mature, the focus is now shifting to one of the most critical aspects of these therapies—the cell donors. We’re excited to announce that this year's summit will address the core questions and challenges surrounding donor characterization, with a special emphasis on: 🔍 Donor Variability 🎯 Donor Selection 🔄 Donor Retention / Consistent Donor Supply 📈 Scalability / Safety & Efficacy We've collaborated with leading companies in the Cell Therapy space, including Sana Biotech, Poseida Therapeutics, and BMS, to craft an agenda that will propel this emerging field even further. Don't miss out on this opportunity to be part of the conversation that's shaping the future of cell therapy! #CellTherapy #DonorSelection #AllogeneicTherapy #Biotech #HealthcareInnovation The full agenda can be viewed here: https://lnkd.in/eJRRzzhU

Cytonus Therapeutics, a small biotech company north of San Diego, raised $11.7 million in Series A #financing to engineer cells as delivery vessels for genetic medicines, including mRNA therapies and oncolytic viruses for cancer, Endpoints News has learned. The unconventional approach flips the script on cell therapy. Rather than using the cell as a #medicine itself, a partially-gutted cell transports a drug to a specified address in the body, thanks to molecular homing beacons appended to its surface. Cytonus Therapeutics is a San Diego-based #biotech company that has developed a vast platform of proprietary immunotherapeutic products to treat a wide range of medical conditions including cancers, infectious diseases, inflammatory diseases, and cognitive disorders, and to improve patient outcomes. Its proprietary Cargocyte™ technologies are next-generation #biomolecular delivery devices which have numerous medical applications across unmet therapeutic areas. Cytonus Therapeutics Remo Moomiaie-Qajar M.D. Richard Klemke, Ph.D. #cytonus #startup #funding